Trials / Completed
CompletedNCT00394810
Efficacy and Pharmacodynamic Study of Panzem® NCD in Patients With Hormone-Refractory Prostate Cancer
Phase 2 Efficacy and Pharmacodynamic Study of 2-Methoxyestradiol Nanocrystal Colloidal Dispersion(Panzem® NCD) in Patients With Taxane-Refractory, Metastatic,Hormone-Refractory Prostate Cancer
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 21 (actual)
- Sponsor
- CASI Pharmaceuticals, Inc. · Industry
- Sex
- Male
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This open-label, multicenter, Phase 2 trial, will assess the anti tumor activity, safety and pharmacokinetics, of Panzem® NCD in patients with metastatic, docetaxel refractory, androgen-independent prostate cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Panzem® NCD | suspension, 100 mg/mL, four times daily continuous dosing |
Timeline
- Start date
- 2006-11-01
- Primary completion
- 2008-11-01
- Completion
- 2008-11-01
- First posted
- 2006-11-01
- Last updated
- 2008-11-25
Locations
4 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00394810. Inclusion in this directory is not an endorsement.